Funktionsmenü_neu


Hauptnavigation


Sub-Navigation
Klickpfad

Signal Transduction Inhibitor BAY 43-9006 at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

June 5 to June 8, 2004

  

Press release:

Encouraging Interim Results on BAY 43-9006 in Advanced Kidney Cancer Presented at American Society of Clinical Oncology (ASCO) Meeting
Data Show Durable Responses in Addition to TumorShrinkage and Disease Stabilization

  PDF / 203 KB collectRCC_20040607-IR-0319_e.pdf

  

Press release:

Encouraging Data on BAY 43-9006 in Combination with Standard Chemotherapeutics as Melanoma Treatment Presented at American Society of Clinical Oncology Meeting
40 Percent of Patients have Durable Partial Responses

  PDF / 159 KB collectMelanoma_20040607-IR-0320_e.pdf

  

BAY 43-9006 Fact Sheet:

  PDF / 188 KB collectBay439006_FactSheet.pdf

BAY 43-9006 Clinical Trial Overview:

  PDF / 61 KB collectClinicalTrials.pdf

Background Information on Renal Cell Cancer:

  PDF / 152 KB collectRCC_Backgrounder.pdf

Background Information on Melanoma:

  PDF / 27 KB collectMelanoma_Backgrounder.pdf

List of BAY 43-9006 Presentations at ASCO 2004:

  PDF / 172 KB collectASCO_Schedule.pdf

ASCO 2004 Abstracts and Oral Presentations on BAY 43-9006

Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial: Abstract No: 4501

Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma: Abstract No: 7507

A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: A National Cancer Institute of Cancer Clinical Trials Group Study: Abstract No: 6611

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer: Abstract No: 3059

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors: Abstract No: 3049

Novel methodology of response assessment in hepatocellular carcinoma – Assessing response by change in tumor enhancement in distinction from conventional means: Abstract No: 3107

Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors: Abstract No: 3056

Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension: Abstract No: 2035

BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience: Abstract No: 7506

  

Glossary of Terms:

  PDF / 136 KB collectGlossary.pdf

Useful Links:

ASCO Homepage: www.asco.org

Clinical trials information: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

Information on renal cell cancer: www.kidneycancerassociation.org

Information on melanoma: www.melanomainternational.org

nach oben

You are leaving the Bayer AG website.

Bayer AG is not responsible for the information on the website to which you are linking.